Non-Invasive Paternal Screening (NIPT)


Advancing Breakthroughs with Genomic Solutions in NIPT


Evolving noninvasive screening options, such as noninvasive prenatal tests (NIPT), offer early genetic screening for chromosomal conditions using just one tube of blood—as early as 10 weeks into a patient’s pregnancy.

NIPT - Accurate information for your patients Reliable, easy, and fast

The Forefront of Prenatal Screening

The verifi Prenatal Test is a noninvasive prenatal test that screens for multiple fetal chromosomal aneuploidies using one tube of maternal blood. The test offers the following benefits:

  • Accurate - Lowest failure rate (0.1%)
  • Reliable - Directly analyzes cell-free fetal and maternal DNA; High detection rate
  • Easy - Noninvasive blood draw, just one tube (7–10 ml); test as early as 10 weeks gestational age (8 weeks of fetal age as determined by date of conception) with no limitations regarding ethnicity, BMI, ART or egg donor cases
  • Fast - Results reported to partner laboratory in 3 - 5 business days after sample receipt (time to report may vary based on partner laboratory providing the test)


  How the Process Works  
  Our verifi NIPT service makes the process seamless – for you and your patient.
Offering your patients the verifi Prenatal Test is easy. Our verifi NIPT service provides the test through regional, reference, and some select national laboratories. These partners send their samples to an Illumina CLIA lab for processing and then reports are sent back to the labs.
Physician recommends and orders test for patient.   Requisition and Informed Consent forms are completed, patient proceeds to blood draw.   Blood sample and test request form are sent back to lab.   Lab processes and analyzes the sample.   Test results are sent to health care professional.
  NIPT Is Noninvasive to the Mother and Baby  
  NIPT analyzes cell free DNA from a maternal blood sample (mixture of fetal and maternal DNA) to screen for common chromosomal conditions including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome).  
NIPT is noninvasive to the mother or baby with high detection rates and low false positives. The American Congress of Obstetricians and Gynecologists (ACOG) and International Society of Prenatal Diagnosis (ISPD), along with other professional societies, have stated that NIPT is an available screening option for all pregnant women.1,2   The Verifi Prenatal Test is one such noninvasive test that screens for aneuploidy of chromosomes 21, 18, and 13. Additional screening is available for sex chromosome aneuploidies and select microdeletions in singleton pregnancies. In twin pregnancies, screening for aneuploidy in chromosomes 21, 18, and 13 and the option to screen for the absence of the Y chromosome is available. The results are reported in approximately 3–5 days after the sample is received. Depending on demand, the time to report may vary.


  Your Partner for Excellent Patient Care  
  Our focus on maternal and fetal health affects everything we do to help you provide the optimal care for your patient.  


Genetic Counselors   Laboratory Directors   Client Services   Educational Support
An in-house group of genetic counselors is available to provide guidance on laboratory results.   Experienced directors manage our state-of-the-art, CAP-accredited, CLIA-certified laboratory.   The Client Services group is on-site and readily available to provide helpful, timely support.   Personalized Genomics is proud to support CME and other educational programs for health care professionals.